BioVaxys Announces Application for Management Cease Trade Order
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") announces that as a result of delays in ...
Aptose Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market Facility
The Committed Equity Facility agreement provides Aptose the right, in its sole option and discretion without obligation, to sell and issue up to $25 million of its common shares (the “Common Shares”) ...
Medicenna Reports Third Quarter Fiscal 2025 Financial and Operational Results and Provides Anticipated Milestones
Disease control rate (DCR) of 78% (7 of 9) in combination escalation arm of MDNA11 with Merck’s (known as MSD outside of Canada and the US) ...
News Medical9h
Study breaks down Alzheimer's treatment effects in clear terms
In the past two years, the Food and Drug Administration has approved two novel Alzheimer's therapies, based on data from clinical trials showing that both drugs slowed the progression of the disease.
Implantica announces positive feedback received from U.S. FDA of the RefluxStop™ PMA Module 2 submission
Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including a unique ...